Thrivent Financial For Lutherans Atara Biotherapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$4.69 - $9.84 $345,380 - $724,637	73,642 New	73,642 $573,000
Q2 2021 Aug 19, 2021	SELL	$12.89 - $16.58 $575,306 - $739,998	-44,632 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $647,360 - $958,092	-46,240 Reduced 50.88%	44,632 $641,000
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $479,673 - $993,041	37,859 Added 71.41%	90,872 $1.78 Million
Q3 2020 Nov 10, 2020	SELL	$11.92 - $15.87 $5,268 - $7,014	-442 Reduced 0.83%	53,013 $687,000
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $304,158 - $950,429	53,455 New	53,455 $455,000

3.07M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $720M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.